Epidemiology, pathology, and genetics of prostate cancer among african americans compared with other ethnicities

Methods in Molecular Biology

Volumn 472, Issue , 2009, Pages 439-453

  Williams, Heinric ^a   Powell, Isaac J ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Genetics; Prostate cancer outcome; Racial differences

Indexed keywords

AFRICAN AMERICAN; COMPARATIVE STUDY; ETHNIC GROUP; ETHNOLOGY; GENETICS; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR; REVIEW; SOCIOECONOMICS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

AFRICAN AMERICANS; ETHNIC GROUPS; HUMANS; MALE; PROSTATIC NEOPLASMS; SOCIOECONOMIC FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 58149461559     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60327-492-0_21     Document Type: Review

References (78)

1. American Cancer Society (2007) Cancer facts and figures 2007. Available at http://www.cancer.org/docroot/STT/stt-0.asp.
2. American Cancer Society (2003) Cancer facts and figures 2003. Available at http://www.cancer.org/docroot/STT/stt-0.asp.
3. Grönberg, H. (2003) Prostate cancer epidemiology. Lancet 361, 859-864.
4. Crawford, E. D. (2003) Epidemiology of prostate cancer. Urology 62 (6) (suppl 1), 3-12.
5. Schaid, D. J. (2004) The complex genetic epidemiology of prostate cancer. Hum Mol Genet, suppl. 13, R103-121.
6. Brawley, O. W. (1998) Prostate cancer and black men. Semin Urol Oncol 16,184-186.
7. American Cancer Society (2007) Cancer facts and figures for AAMs 2007-2008. Available at http://www.cancer.org/docroot/STT/stt-0.asp.
8. Liu, L., Cozen, W., Bernstein, L., Ross, R. K., Deapen, D. (2001) Changing relationship between socioeconomic status and prostate cancer incidence. J Natl Cancer Inst 93, 705-709.
9. Powell, I. J., Gelfand, D. E., Parzuchowski, J, Heilbrun, L., Franklin, A. (1995) A successful recruitment process of African American men for early detection of prostate cancer. Cancer 75, 1880-1884.
10. Robbins, A. S., Whittemore, A.S., Thom, D. H. (2000) Differences in socioeconomic status and survival among white and black men with prostate cancer. Am J Epidemiol 151, 409-416.
11. Powell, I. J., Zhou, J., Sun, Y., Sakr, W. A, Patel, N. P., Heilbrun, L. K., et al. (2004) CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol 172, 1848-1852.
12. Gaston, K. E., Kim, D., Singh, S., Ford 3rd, O. H., Mohler, J.L. (2003) Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 170, 990-993.
13. Mettlin, C. (1997) Recent developments in the epidemiology of prostate cancer. Eur J Cancer 33, 340-347.
14. Jani, A. B., Vaida, F., Hanks, G., Asbell, S., Sartor O., Moul, J.W. et al. (2001) Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer 96, 363-371.
15. Glover Jr, F. E., Coffey, D. S., Douglas, L. L., Cadogan, M., Russell, H., Tulloch, T., et al. (1998) The epidemiology of prostate cancer in Jamaica. J Urol 159, 1984-1986.
16. Delongschamp, N. B., Singh A., Haas, G. P. (2007) Epidemiology of prostate cancer in Africa: Another step in the understanding of the disease? Curr Prob Cancer 31, 226-236.
17. Ahluwalia, B., Jackson, M. A., Jones G. W., Williams, A. O., Rao, M. S., Rajguru S. (1981) Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer 48, 2267-2273.
18. Haenszel, W., Kurihara M. 1968 Study of Japanese migrants. I. Mortality form cancer and other diseases among Japanese in the United States. J. Natl Cancer Inst 40, 43-68.
19. Ries, L. A. G., Eisner M.P., Kosary C.L., Hankey B.F., Miller B.A., Clegg L., et al. (2002) SEER Cancer Statistics Review, 1975-2002, National Cancer Institute. Bethesda, MD. Available at http://seer.cancer.gov/csr/1975-2002/.
20. Chu, K. C., Tarone, R.E., Freeman, H. P. (2003) Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97, 1507-1516.
21. Lu-Yao, G., Albertsen P. C., Stanford J.L., Stukel T.A., Walker-Corkery, E. S., Barry M. J. (2002) Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325, 740.
22. Wild, S.H., Fischbacher, C. M., Brock, A., Griffiths, C., Bhopal, R. (2006) Mortality from all cancers and lung, colorectal, breast and prostate cancer by country of birth in England and Wales, 2001-2003. Br J Cancer 94, 1079-1085.
23. Yu, H., Jarris, R. E., Gao, Y. T., Gao, R., Wynder, E. L. (1991) Comparative epidemiology of cancer of colon, rectum, prostate and breast in Shanghai, China versus the United States. Int J Epidemiol 20, 76-81.
24. Steinberg, G. D., Carter, B. S., Beaty, T. H., Childs, B., Walsh, P. C. (1990) Family history and the risk of prostate cancer. Prostate 17, 337-347.
25. Johns, L. E., Houlston, R. S. (2003) A systematic review and meta-analysis of familial prostate cancer. BJU Intl 91, 789-794.
26. Freedman, M. L., Haiman, C. A., Patterson, N., McDonald, G. J., et al. (2006) Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 103, 14068-14073.
27. Suuriniemi, M., Agalliu, I., Schaid, D. J., Johanneson, B., McDonnell, S. K., et al. (2007) Conformation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev 16, 809-814.
28. Kittles, R. A., Baffoe-Bonnie, A. B., Moses, T. Y., Robbins, C. M., Ahaghotu, C., et al. (2006) A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 43, 507-511.
29. DeVere White, R. W., Deitch, A. D., Jackson, A. G., Gandour-Edwards, R., Marshalleck, J., Soares, S.E., et al. (1998) Racial differences in clinically localized prostate cancers of black and white men. J Urol 159, 1979-1982.
30. Richie, J. P. (1999) Anti-androgens and other hormonal therapies for prostate cancer. Urology 54, 15-18.
31. Kokontis, J. M., Liao, S. (1999) Molecular action of androgen in the normal and neoplastic prostate Vitam Horm 55, 219-307.
32. Culig, Z., Hobisch, A., Bartsch, G., Klocker, H. (2000) Regulation of prostatic growth by peptide growth factors. Prostate 28, 392-405.
33. Parsons, J. K., Carter, H. B., Platz, E. A., Wright, E. J., Landis, P., Metter, E. J. (2005) Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 14, 2257-2260.
34. Hsing, A. W., Comstock, G. W. (1993) Serological precursors of cancer: serum hormone and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev, 2, 27-32.
35. Platz, E. A., Leitzmann, M. F., Rifai, N., Kantoff, P. W., Chen, Y. C., Stampfer, M. J., Willet. W. C., Giovannucci, E. (2005) Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14, 1262-1269.
36. Ellis, L., Nyborg, H. (1992) Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids 57, 72-75.
37. Zeegers, M. P., Kiemeney, L. A., Nieder, A. M., Ostrer, H. (2004) How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev 13, 1765-1771.
38. Soronen, P., Laiti, M., Torn, S., Harkonen, P., Patrikainen, L., Li, Y., et al. (2004) Sex steroid hormone metabolism and prostate cancer. Ster Biochem Mol Biol 92, 281-286.
39. Giovannucci E., Stampfer M. J., Krithivas K., Brown, M., Dahl, D., et al. (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 94, 3320-3323.
40. Bratt O., Borg A., Kristoffersson U., Lundgren, R., Zhang, Q. X., Olsson, H. (1999) CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 81, 672-676.
41. Nam R. K., Elhaji, Y., Krahn, M. D., Lee, S. H., Kim, C. C., Hahn, S. H., et al. (2000) Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 164, 567-572.
42. Gilligan, T., Manola, J., Sartor, O., Weinrich, S. P., Moul, J. W., Kantoff, P. W. (2004) Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer 3, 98-103.
43. Powell, I. J., Land, S. J., Dey, J., Heilbrun, L.K., Hughes, M.R., Sakr, W., et al. (2005) Impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer 103, 528-537.
44. Balic, I., Graham, S. T., Troyer, D. A., Higgins, B. A., Pollock, B. H., Johnson-Pais, T. L., Thompson, I. M., Leach, R. J. (2002) Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol 168, 2245-2248.
45. Hsing A. W., Gao Y. T., Wu, G., Wang, X., Deng, J., Chen, Y. L., et al. (2000) Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China. Cancer Res 60, 5111-5116.
46. Correa-Cerro L., Wohr G., Haussler J., Berthon, P., Drelon, E., Mangin, P., et al. (1999) (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet 7, 357-362.
47. Ntais, C., Polycarpou, A., Ioannidis, J.P. (2003) Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 12, 120-126.
48. Rebbeck, T.R., Jaffe, J.M., Walker, A.H., Wein, A.J., Malkowicz, S.B. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90, 1225-1229.
49. Bangsi, D., Zhou, J.Y., Sun, Y., Patel, N. P., Darga, L. L., Heilbrun, L. K., et al. (2006) Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men, Urol Oncol 24, 21-27.
50. Makridakis, N, M., di Salle, E., Reichardt, J. K. (2000) Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 10, 407-413.
51. Winters, D. L., Hanlon, A.L., Raysor, S. L., Watkins-Bruner, D., Pinover, W. H., et al. (2001) Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer. Urology 58, 614-618.
52. Wang, C., Catlin, D. H., Starcevic, B., Heber, D., Ambler, C., Berman, N., et al. (2005) Low-fat high-fiber diet decreased serum and urine androgens in men. J Clin Endocrinol Metab 90, 3550-3559.
53. Griffiths, K., Morton, M. S., Denis, L. (1999) Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer. Eur Urol 35, 443-455.
54. Buschemeyer, W. C., Freedland, S. J. (2007) Obesity and prostate cancer, epidemiology and clinical implications. Eur Urol 52, 1-13.
55. Amling, C. L., Riffenburgh, R.H., Sun, L., Moul, J.W., Lance, R.S., Kusuda, L., et al. (2004) Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22, 439-445.
56. Clinton, S. K., Emenhiser, C., Schwartz, S. J., et al. (1996) Cis-trans lycopene isomers, carotenoids, and retinol in human prostate cancer. Cancer Epidemiol Biomarkers Prev 5, 823-833.
57. Giovannucci, E., Rimm, E. B., Liu Y., Stampfer, M. J., Willett, W. C. (2002) A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94, 391-398.
58. Kirsh V. A., Mayne, S. T., Peters, U., Chatterjee, N., Leitzmann, M. F., Dixon, L. B., Urban, D. A., Crawford, E. D., Hayes, R. B. (2006) A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15, 92-98.
59. Thorpe, J. F., Jain S., Marczylo, T. H., Gescher, A. J., Steward, W. P., Mellon, J. K. (2007) A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl 89, 207-211.
60. Moul, J. W., Sesterhenn, I. A., Connelly, R. R., Douglas, T., Srivastava, S., Mostofi, F. K., et al. (1995) Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 274, 1277-1281.
61. Sakr, W. A., Grignon, D. J., Hass, G., Heilbrun, L. K., Pontes, J. E., Crissman, J. D. (1996) Age and racial distribution of prostate intraepithelial neoplasia. Eur Urol 30, 138-144.
62. Hoffman, R. M., Gilliland, F. D., Eley, J. W., Harlan, L. C., Stephenson, R.A., Stanford, J. L., et al. (2001) Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93, 388-395.
63. Moul, J. W., Connelly, R. R., Mooneyhan, R. M., Zhang,W., Sesterhenn, I. A., Mostofi, F. K., et al. (1999) Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol 162, 394-397.
64. Ndubuisi, S.C., Kofie, V. Y., Andoh, J. Y., Schwartz, E. M. (1995) Black-white differences in the stage at presentation of prostate cancer in the District of Columbia. Urology 46, 71-77.
65. Shavers, V. L., Brown, M. L. (2002) Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94, 334-357.
66. Harlan, L. C., Potosky, A., Gilliland, F. D., Hoffman, R., Albertsen, P. C., Hamilton, A. S., et al. (2001) Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 93, 1864-1871.
67. Morris, C. R., Snipes, K. P., Schlag, R., Wright, W. E. (1999) Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control 10, 503-511.
68. Klabunde, C. N., Potosky, A. L., Harlan, L. C., Kramer, B. S. (1998) Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care 36, 1337-1348.
69. Underwood, W., De Monner, S., Ubel, P., Fagerlin, A., Sanda, M. G., Wei, J. T. (2004) Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol 171, 1504-1507.
70. Shavers, V. L., Brown, M. L., Potosky, A. L., Klabunde, C. N., Davis, W.W., Moul, J.W., et al. (2004) Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. Gen Intern Med 19, 146-155.
71. Optenberg, S. A., Thompson, I. M., Friedrichs, P., Wojcik, B., Stein, C. R., Kramer, B. (1995) Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA 274, 1599-1605.
72. Moul, J. W., Wu, H., Sun, L., McLeod, D. G., Amling, C., Lance, R., et al. (2002) Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 132, 213-219.
73. Powell, I.J., Schwartz, K., Hussain, M. (1995) Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology 46, 825-830.
74. Moul, J. W., Douglas, T. H., McCarthy, W. F., McLeod, D. G. (1996) Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 155, 1667-1673.
75. Iselin, C. E., Box, J. W., Vollmer, R. T., Layfield, L. J., Robertson, J.E., Paulson, D.F. (1998) Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer 83, 2353-2360.
76. Powell, I.J., Dey, J., Dudley, A., Pontes, J.E., Cher, M.L., Sakr, W., et al., (2002) Disease-free survival difference between African-Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology 59, 907-912.
77. Grossfeld, G.D., Latini, D.M., Downs, T., Lubeck, D.P., Mehta, S.S., Carroll, P.R. (2002) Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol 168, 2510-2515.
78. Powell, I.J., Banerjee, M., Bianco, F.J., Wood Jr, D.P., Dey, J., Lai, Z., et al. The effect of race/ethnicity on prostate cancer treatment outcome is conditional: a review of Wayne State University data. J Urol 171 (2004), 1508-1512.